Ceftazidime, a third-generation cephalosporin antibiotic, remains one of the most critical antimicrobial agents in global healthcare. Its efficacy against a broad spectrum of Gram-negative bacteria, including Pseudomonas aeruginosa, makes it indispensable in hospital settings for treating severe infections such as pneumonia, urinary tract infections, skin infections, and intra-abdominal infections. As the global demand for injectable antibiotics continues to rise, understanding the Ceftazidime global buyers list has become essential for manufacturers, suppliers, and procurement professionals navigating this dynamic pharmaceutical market. The Ceftazidime injection market was valued at approximately USD 700 million in 2024 and is projected to reach USD 1.2 billion by 2035, growing at a compound annual growth rate (CAGR) of…